Periodontal DiseasesPhase 3NCT05418621
Does the Non-surgical Application of Enamel Matrix Derivative Reduce the Need of Periodontal Surgical Intervention in Subjects With Severe (Stage III) Periodontitis?
A Phase 3 study testing Enamel Matrix Derivative application and Saline application in people with Periodontal Diseases, run by University of Pisa at 2 sites in Italy.
Trial summary
Periodontal treatment relies on a sequential series of different phases that are usually incapsulated in three main phases: non-surgical treatment, surgical phase and, finally, supportive phase. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Periodontal Diseases
- What is being tested?
- Enamel Matrix Derivative application and Saline application
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 140 participants
- Where
- 2 sitesItaly
- Study dates
- 1 Mar 2021to Jun 2025
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Accept the form of the study and signs a declaration of informed consent; understand and are willing, able and likely to comply with all study procedures and restrictions.
- Systemically healthy (according to exclusion criteria 4) participants of either genders who are attending a periodontal centre for periodontal care.
- Aged 18 or over.
- Presenting at least 20 teeth (excluded wisdom teeth).
- Being affected by generalized Periodontitis (stage III) irrespectively of the grade (Tonetti et al., 2018) i.e. presenting at least 5 mm of clinical atattachment loss at the interdental areas, radiographic bone resorption of more than 30% of the root length extending to at least the middle portion of the root, less than 5 teeth lost for periodontal reason, presenting characteristics for complexity (intrabony defects, furcation defects, moderate ridge defects)
- Bleeding on probing on at least 30% of the sites and a minimum of 4 teeth with at least one site with PPD ≥6mm
Who cannot join
- Persons incapable of responding to the questions.
- An employee of the sponsor, employee of the general dental practice, and/or a family relative of the employees mentioned above.
- Women known to be pregnant or lactating (a specific declaration form will be signed by the patient, stating the non-pregnant or lactating status).
- Persons suffering of pathologies known to affect the outcome of periodontal therapy (i.e. diabetes, osteoporosis, immunosuppression).
- Persons undergoing therapy which will may complicate adherence to protocol or showing an impact on periodontal outcome (i.e. chemotherapy and immunosuppressive treatments).
- Persons who require antibiotic coverage (following infectious endocarditis, using prosthetic cardiac valves, other pathologies).
Show all 14Show fewer
- Persons undergoing pharmacological treatment associated with gingival hypertropia development (phenytoin, phenobarbital, lamotrigine, vigabatrin, ethosuximide, topiramate, primidone, nifedipine, amlodipine, verapamil, cyclosporine).
- Persons with implant-supported restorations affected by peri-implantitis (as defined by the 2017 Classification, i.e. presence of bleeding and/or suppuration on gentle probing, probing depths of ≥6 mm, bone levels ≥3 mm apical of the most coronal portion of the intraosseous part of the implant).
- Smokers declaring to smoke more than 20 cigarettes per day.
- Persons with Body Mass Index above 29(obese subjects).
- Anyone who in the investigators' opinion is not suitable to take part in the study.
- Allergy/idiosyncrasy to anaesthesia or components of the device object of the study.
- Previous periodontal subgingival instrumentation within the previous 12 months.
- Antibiotics intake in the previous 3 months.
Trial locations and contacts
2 sites in 1 country.
Italy2 sites, 2 recruiting
- Recruiting
University Hospital of Pisa
Pisa, 56121
Filippo Graziani, DDS, PhD, 0039050992939, filippo.graziani@med.unipi.it
- Recruiting
Azienda Ospedaliero Universitaria Pisana
Pisa
Filippo Graziani, DDS, 0039050992939, filippo.graziani@unipi.it
About this study
Official title: Does the Non-surgical Application of Enamel Matrix Derivative Reduce the Need of Periodontal Surgical Intervention in Subjects With Severe (Stage III) Periodontitis? A Randomized, Multicenter, Clinical Trial
Periodontal treatment relies on a sequential series of different phases that are usually incapsulated in three main phases: non-surgical treatment, surgical phase and, finally, supportive phase. Whilst, on the one hand not all patients may undergo surgical interventions, on the other hand non-surgical periodontal and supportive treatment are administered to all subjects affected by periodontitis. Both phases are constituted by closed, non-surgical, root instrumentation which is often carried out with similar techniques. Thus, non-surgical periodontal treatment (NSPT) is the one key stone of the treatment of periodontitis.
NSPT is very efficacious. A significant majority of the diseased sites are usually managed non-surgically (Graziani et al., 2017)). Moreover, bleeding on probing and symptoms are significantly decreased by NSPT. Importantly, NSPT is also capable to reduce systemic inflammation (Teeuw et al., 2014), improve glycaemic control (Sanz et al., 2018) and overall ameliorate oral health related quality of life (Graziani, Music, et al., 2019). Lastly, NSPT is cost effective as its costs are moderate and it may be performed by both dentists and hygienists.
Read more
Nevertheless, NSPT is often uncapable to solve an entire clinical case and surgical treatment is advocated as in fact the complete closure of the pockets ranges from 57 to 75% according to a follow-up of 3⁄4 months or 6/8 respectively (Solini et al., 2019). Periodontal surgery is also effective, but it is nonetheless a surgical intervention which cannot be defined as deprived of side effects (Graziani et al., 2018).
Thus, in order to improve the outcome of NSPT numerous adjunctive treatment modalities have been advocated (Braun et al., 2008; Graziani et al., 2017; Haffajee et al., 2003). Yet the objective of reducing the need for surgery has been rarely evaluated.
Recently, our group ran a trial in which enamel matrix derivatives (EMD) has been applied as non-surgical adjunct. The findings highlighted that EMD application lowers systemic inflammation, increases blood clot stability and, locally, reduces of the need for surgery by 32% compared to the control group without EMD.
Thus, a multicentre responding to the following questions:
- Flapless application of EMD reduce the need for periodontal surgery?
- Are the results stable over time?
- Can the results be generalized among different clinicians? EMD is a resorbable, implantable material and supports periodontal regeneration, which takes place over more than a year. It consists of hydrophobic enamel matrix proteins extracted from developing embryonal enamel of porcine origin in a propylene glycol alginate carrier.
The gel has a suitable viscosity to facilitate application directly onto root surfaces exposed during periodontal surgery. Once applied onto an exposed root surface the protein self assembles into an insoluble three-dimensional matrix and creates a suitable environment for selective periodontal cell migration and attachment, which re-establishes lost tooth supporting tissues. Subsequent to formation of new attachment, alveolar bone can also be regenerated due to the osteogenic capacity of the restored periodontal ligament. EMD is degraded by enzymatic processes of normal wound healing.
- Conditions
- Periodontal Diseases
- Being tested
- Enamel Matrix Derivative application, Saline application
- Medical subject headings
- Periodontal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Enamel Matrix Derivative applicationDrug
in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
Saline applicationOther
in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
| Study group | Role | What they receive |
|---|---|---|
| Enamel Matrix Derivative application | Experimental | At the completion of the subgingival instrumentation, in all sites with PPD>6 mm, a solution of 24% EDTA, will be first applied with a sterile syringe with a thin blunt tip (25GX1/4"). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues. Receives: Drug: Enamel Matrix Derivative application |
| Saline application | Placebo comparator | At the completion of the subgingival instrumentation, in all sites with PPD>5 mm, a solution of 24% EDTA , will be first applied with a sterile syringe with a thin blunt tip (25GX1/4"). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues. Receives: Other: Saline application |
What is being measured
The primary outcome is the main question the study is designed to answer.
Resolved cases
inter-group differences in % of cases, patient-level analysis, with complete absence of sites with Probing Pocket Depth (PPD) >=6mm
Measured: 3, 6 and 12 months after treatment
Secondary outcomes (20)
number of sites with PPD>=6mm
Intra-group and intergroup changes in % and number of sites with PPD>=6mm. The Probing Pocket Depth (PPD) will be measured as the distance between the gingival margin and the deepest part of the gingival pocket measured through a University of North Carolina -15 periodontal probe (UNC-15) (Hu-Friedy, USA). PPD will be evaluated at 6 sites on each tooth: disto-buccal, buccal, mesio-buccal, disto-lingual, lingual, mesio-lingual. Each measure will be rounded to the nearest millimetre probe.
Measured: 3, 6 and 12 months after treatment
changes in Full Mouth Plaque Score (FMPS)
intragroup and intergroup change in Full Mouth Plaque Score. The Full Mouth Plaque Score (FMPS) will be measured as the presence or absence of plaque on each tooth surface will be assessed. The bacterial deposits are stained with a plaque-disclosing solution (erythrosine). Areas adjacent to the gingival margins that exhibit an intense staining that can be easily removed with the edge of the probe will be dotted as having plaque. The presence of plaque will be evaluated as 1, while the absence as 0 on 6 areas per tooth (disto-buccal, buccal, mesio- buccal, disto-lingual, lingual, mesio-lingual). A dedicated diagram (see attached medical records, chapter 16) will allow to draw the overall plaque accumulation and mean plaque score will be indicated in percentage (% of sites found positive for the presence of plaque on the total of 6 sites per tooth (O'Leary et al., 1972).
Measured: 3, 6 and 12 months after treatment
changes in Full Mouth Bleeding Score (FMBS)
intragroup and intergroup change in Full Mouth Bleeding Score. The Full Mouth Bleeding Score (FMBS) will be measured dichotomously after periodontal probing. It will be considered positive when the bleeding occurs after the retraction of the probe (approximate time for evaluation 30 seconds after probe insertion). It will be considered negative when there is no bleeding. The mean bleeding score is indicated in percentage (% of sites detected positive for bleeding on the total 6 sites per tooth )(Ainamo \& Bay, 1975).
Measured: 3, 6 and 12 months after treatment
mean values of PPD
Intra-group and intergroup changes in terms of full mouth mean values of PPD. The Probing Pocket Depth (PPD) will be measured as the distance between the gingival margin and the deepest part of the gingival pocket measured through a University of North Carolina -15 periodontal probe (UNC-15) (Hu-Friedy, USA). PPD will be evaluated at 6 sites on each tooth: disto-buccal, buccal, mesio-buccal, disto-lingual, lingual, mesio-lingual. Each measure will be rounded to the nearest millimetre probe.
Measured: 3, 6 and 12 months after treatment
mean values of recession (REC)
Intra-group and intergroup changes in terms of full mouth mean values of REC. The Recession (Rec) will be measured as the distance in mm from the cement-enamel junction (CEJ) to the gingival margin measured through UNC- 15. In the event that CEJ would not be available, one of the following clinical landmarks will be used: crown margin, restored margin, occlusal point.
Measured: 3, 6 and 12 months after treatment
mean values Clinical Attachment Level (CAL)
Intra-group and intergroup changes in terms of full mouth mean values of CAL. CAL will be calculated as the sum of PPD and REC.
Measured: 3, 6 and 12 months after treatment
Furcation involvement
Intragroup and intergroup changes in terms of furcations degree. Furcation (FI): furcation involvements will be classified according to horizontal probing with Naber's probe in degree I when the probe can enter the orifice of the furcation, degree II when the probe can enter the furcation freely without passing it completely. Class III will be scored when the tip of the Nabers probe will see appearing through the opposite cervice, i.e. "through-and.through" furcation in both mandibular and maxillary molar (Hamp et al., 1975).
Measured: 3, 6 and 12 months after treatment
Dentine sensitivity (Schiff test)
Intra-group and intergroup changes of dentine hypersensitivity as measured with the Schiff test. Schiff test: dentine sensitivity will be assessed trough the study timepoints as reported further using a validated a well described test as the Schiff test (Schiff et al., 1994). The Schiff test is a non-invasive and safety test that consist in spraying air on the tooth and collecting the reaction of the patient in a liker type scale as follows:
- 0 Subject does not respond to air stimulus;
- 1 Subject responds to air stimulus but does not request discontinuation of stimulus;
- 2 Subject responds to air stimulus and requests discontinuation of stimulus;
- 3 Subject responds to air stimulus, considers stimulus to be painful and requests discontinuation of stimulus.
Measured: 3, 6 and 12 months after treatment
Oral Health Impact profile 14
Oral Health Index Profile-14 (OHIP-14): a validated questionnaire of 14 question aiming at assessing statements grouped in 7 conceptual subscales: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability and handicap. It allows an evaluation of the OHRQoL (Slade, 1997). The higher the score, the higher the impact of periodontitis on the patients quality of life
Measured: 3, 6 and 12 months after treatment
Attention Network Task
Attention Network Task (ANT; Fan et al., 2002): a task designed to test three attentional networks: alerting, orienting, and executive control.The higher the score, the higher the cognitive abilities.
Measured: 3, 6 and 12 months after treatment
Corsi block-tapping test
Corsi block-tapping test (CBTT; Orsini et al., 1987): a task to assess visuo-spatial short-term memory. The higher the score the better the cognitive ability
Measured: 3, 6 and 12 months after treatment
Tower of London
Tower of London (ToL; Shallice, 1982): a task designed to evaluate problem-solving and planning capabilities.The higher the score the better the cognitive abilities
Measured: 3, 6 and 12 months after treatment
Sickness Questionnaire
Sickness Questionnaire ( SicknessQ ; Andreasson et al., 2018): a brief instrument, composed of 10 items, aimed to assess perceived sickness behaviour. The higher the score the higher the perceived thickness
Measured: 3, 6 and 12 months after treatment
Depression Anxiety Stress Scale
Depression Anxiety Stress Scale - 21 (DASS-21; Lovibond \& Lovibond, 1995): self - report questionnaire designed to assess the symptoms of depression, anxiety and stress. The higher the score the higher the symptoms of depression, anxiety and stress.
Measured: 3, 6 and 12 months after treatment
State-Trait Anxiety Inventory_ Form
State-Trait Anxiety Inventory_ Form Y2 ( STAI_Y2; Spielberger, 1983): self - report questionnaire aimed to investigate trait anxiety that refers to relatively stable individual differences in anxiety proneness, that is, to differences between people in the tendency to perceive stressful situation as dangerous or threatening. The higher the score the higher the tendency os being prone to anxiety.
Measured: 3, 6 and 12 months after treatment
State-Trait Anxiety Inventory_ Form Y1
State-Trait Anxiety Inventory_ Form Y1 ( STAI_Y1; Spielberger, 1983): self - report questionnaire aimed to investigate trait anxiety that refers to a palpable reaction or process taking place at a given time and level of intensity. The higher the score the higher the trait of anxiety assessed.
Measured: 3, 6 and 12 months after treatment
Profile Mood State
Profile of Mood State (POMS; Grove, Robert \& Prapavessis, 2016): self - report questionnaire aimed to investigate different mood states like.: tension, depression, anger, fatigue, confusion and vigour.
Measured: 3, 6 and 12 months after treatment
Sleep quality
Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 1989): self-assessment scale that provides a reliable, valid and standardized measure of sleep quality. The higher the score the better the sleep quality
Measured: 3, 6 and 12 months after treatment
The Insomnia Severity Index
The Insomnia Severity Index (ISI; Morin, 1993): is a self-report questionnaire designed to assess the nature, severity and daytime impact of insomnia. The higher the score the higher the severity of insomnia.
Measured: 3, 6 and 12 months after treatment
Epworth Sleepiness Scale
Epworth Sleepiness Scale (ESS; Johns, 1991): is a self-assessment tool consisting of 8 items that investigate the general level of daytime sleepiness or the propensity to sleep during different situations of daily life. The higher the score the higher the daily sleepiness.
Measured: 3, 6 and 12 months after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2022
- Study start1 Mar 2021
- Primary completionSep 2024 (estimated)
- Study completionJun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 140 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Pisa
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Filippo Graziani, DDS MClinDent PhD, University of Pisa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05418621
- Sponsor's protocol ID
- PERIO-EMD 3
- Status last verified
- Nov 2022
- First submitted
- 9 Jun 2022
- Last updated
- 3 Nov 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does the Non-surgical Application of Enamel Matrix Derivative Reduce the Need of Periodontal Surgical Intervention in Subjects With Severe (Stage III) Periodontitis? A Randomized, Multicenter, Clinical Trial
- ClinicalTrials.gov ID
- NCT05418621
- Acronym / sponsor ID
- PERIO-EMD 3
- Conditions
- Periodontal Diseases
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 140 participants (estimated)
- Lead sponsor
- University of PisaUniversity, hospital or other
- Study start
- 1 Mar 2021 (actual)
- Primary completion
- Sep 2024 (estimated)
- Study completion
- Jun 2025 (estimated)
- First posted
- 14 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Periodontal treatment relies on a sequential series of different phases that are usually incapsulated in three main phases: non-surgical treatment, surgical phase and, finally, supportive phase. Whilst, on the one hand not all patients may undergo surgical interventions, on the other hand non-surgical periodontal and supportive treatment are administered to all subjects affected by periodontitis. Both phases are constituted by closed, non-surgical, root instrumentation which is often carried out with similar techniques. Thus, non-surgical periodontal treatment (NSPT) is the one key stone of the treatment of periodontitis.
NSPT is very efficacious. A significant majority of the diseased sites are usually managed non-surgically (Graziani et al., 2017)). Moreover, bleeding on probing and symptoms are significantly decreased by NSPT. Importantly, NSPT is also capable to reduce systemic inflammation (Teeuw et al., 2014), improve glycaemic control (Sanz et al., 2018) and overall ameliorate oral health related quality of life (Graziani, Music, et al., 2019). Lastly, NSPT is cost effective as its costs are moderate and it may be performed by both dentists and hygienists.
Nevertheless, NSPT is often uncapable to solve an entire clinical case and surgical treatment is advocated as in fact the complete closure of the pockets ranges from 57 to 75% according to a follow-up of 3⁄4 months or 6/8 respectively (Solini et al., 2019). Periodontal surgery is also effective, but it is nonetheless a surgical intervention which cannot be defined as deprived of side effects (Graziani et al., 2018).
Thus, in order to improve the outcome of NSPT numerous adjunctive treatment modalities have been advocated (Braun et al., 2008; Graziani et al., 2017; Haffajee et al., 2003). Yet the objective of reducing the need for surgery has been rarely evaluated.
Recently, our group ran a trial in which enamel matrix derivatives (EMD) has been applied as non-surgical adjunct. The findings highlighted that EMD application lowers systemic inflammation, increases blood clot stability and, locally, reduces of the need for surgery by 32% compared to the control group without EMD.
Thus, a multicentre responding to the following questions:
- Flapless application of EMD reduce the need for periodontal surgery?
- Are the results stable over time?
- Can the results be generalized among different clinicians? EMD is a resorbable, implantable material and supports periodontal regeneration, which takes place over more than a year. It consists of hydrophobic enamel matrix proteins extracted from developing embryonal enamel of porcine origin in a propylene glycol alginate carrier.
The gel has a suitable viscosity to facilitate application directly onto root surfaces exposed during periodontal surgery. Once applied onto an exposed root surface the protein self assembles into an insoluble three-dimensional matrix and creates a suitable environment for selective periodontal cell migration and attachment, which re-establishes lost tooth supporting tissues. Subsequent to formation of new attachment, alveolar bone can also be regenerated due to the osteogenic capacity of the restored periodontal ligament. EMD is degraded by enzymatic processes of normal wound healing.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Enamel Matrix Derivative application | Experimental | Drug: Enamel Matrix Derivative applicationAt the completion of the subgingival instrumentation, in all sites with PPD>6 mm, a solution of 24% EDTA, will be first applied with a sterile syringe with a thin blunt tip (25GX1/4"). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues. |
| Saline application | Placebo comparator | Other: Saline applicationAt the completion of the subgingival instrumentation, in all sites with PPD>5 mm, a solution of 24% EDTA , will be first applied with a sterile syringe with a thin blunt tip (25GX1/4"). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Accept the form of the study and signs a declaration of informed consent; understand and are willing, able and likely to comply with all study procedures and restrictions.
- Systemically healthy (according to exclusion criteria 4) participants of either genders who are attending a periodontal centre for periodontal care.
- Aged 18 or over.
- Presenting at least 20 teeth (excluded wisdom teeth).
- Being affected by generalized Periodontitis (stage III) irrespectively of the grade (Tonetti et al., 2018) i.e. presenting at least 5 mm of clinical atattachment loss at the interdental areas, radiographic bone resorption of more than 30% of the root length extending to at least the middle portion of the root, less than 5 teeth lost for periodontal reason, presenting characteristics for complexity (intrabony defects, furcation defects, moderate ridge defects)
Key exclusion criteria (14 listed)
- Persons incapable of responding to the questions.
- An employee of the sponsor, employee of the general dental practice, and/or a family relative of the employees mentioned above.
- Women known to be pregnant or lactating (a specific declaration form will be signed by the patient, stating the non-pregnant or lactating status).
- Persons suffering of pathologies known to affect the outcome of periodontal therapy (i.e. diabetes, osteoporosis, immunosuppression).
- Persons undergoing therapy which will may complicate adherence to protocol or showing an impact on periodontal outcome (i.e. chemotherapy and immunosuppressive treatments).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Enamel Matrix Derivative applicationin the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues. | Drug | Enamel Matrix Derivative application |
| Saline applicationin the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues. | Other | Saline application |
Primary outcome
Resolved cases
Time frame: 3, 6 and 12 months after treatment
inter-group differences in % of cases, patient-level analysis, with complete absence of sites with Probing Pocket Depth (PPD) >=6mm
20 secondary outcomes
number of sites with PPD>=6mm
Time frame: 3, 6 and 12 months after treatment
changes in Full Mouth Plaque Score (FMPS)
Time frame: 3, 6 and 12 months after treatment
changes in Full Mouth Bleeding Score (FMBS)
Time frame: 3, 6 and 12 months after treatment
mean values of PPD
Time frame: 3, 6 and 12 months after treatment
mean values of recession (REC)
Time frame: 3, 6 and 12 months after treatment
mean values Clinical Attachment Level (CAL)
Time frame: 3, 6 and 12 months after treatment
Furcation involvement
Time frame: 3, 6 and 12 months after treatment
Dentine sensitivity (Schiff test)
Time frame: 3, 6 and 12 months after treatment
Oral Health Impact profile 14
Time frame: 3, 6 and 12 months after treatment
Attention Network Task
Time frame: 3, 6 and 12 months after treatment
Corsi block-tapping test
Time frame: 3, 6 and 12 months after treatment
Tower of London
Time frame: 3, 6 and 12 months after treatment
Sickness Questionnaire
Time frame: 3, 6 and 12 months after treatment
Depression Anxiety Stress Scale
Time frame: 3, 6 and 12 months after treatment
State-Trait Anxiety Inventory_ Form
Time frame: 3, 6 and 12 months after treatment
State-Trait Anxiety Inventory_ Form Y1
Time frame: 3, 6 and 12 months after treatment
Profile Mood State
Time frame: 3, 6 and 12 months after treatment
Sleep quality
Time frame: 3, 6 and 12 months after treatment
The Insomnia Severity Index
Time frame: 3, 6 and 12 months after treatment
Epworth Sleepiness Scale
Time frame: 3, 6 and 12 months after treatment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Periodontal Diseases
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation
Periodontal Disease
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Enamel Matrix Derivative application and Saline application in people with Periodontal Diseases, run by University of Pisa at 2 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Resolved cases (time frame: 3, 6 and 12 months after treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2022.